Terns Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Terns Pharmaceuticals, Inc. - overview
Established
2017
Location
Foster City, CA, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in California, US, Terns Pharmaceuticals, Inc. operates as a biotechnology company that develops treatments for patients with chronic liver diseases. The company was founded by CEO Senthil Sundaram. Terns Pharmaceuticals has raised a total of USD 197 million over 3 funding rounds.
In February 2021, Terns Pharmaceuticals announced the pricing of upsized Initial Public Offering for USD 127. 5 million and selling 7. 5 million shares at USD 17 per share on the NASDAQ. Terns Pharmaceuticals operates as a clinical-stage biopharmaceutical company that develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
Terns’ program called TERN-101 a liver-distributed, nonsteroidal, non-bile acid FXR agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient intestinal FXR activation. Terns Pharmaceuticals plans to list on the Nasdaq global select market under the ticker symbol TERN.
Current Investors
Lilly Asia Ventures, OrbiMed Advisors, Vivo Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ternspharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.